Grażyna Biała

Grażyna Biała is a Professor at the Chair and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy, Medical University of Lublin. She holds a PharmD and DSc and has been a key figure in pharmacological research, particularly in neuropharmacology and behavioral models of cognitive and psychiatric disorders.

Research Interests: Her work centers on understanding drug effects on memory, learning, anxiety, and stress using animal models (mice and rats). She investigates mechanisms involving NMDA receptors, calcium signaling, nicotine, and novel compounds targeting cognitive impairment and mood disorders. Her research integrates pharmacodynamics with behavioral neuroscience to explore both pathological mechanisms and potential therapeutics.

The analysis of her recent publications reveals a consistent focus on neuropharmacological interventions in cognitive and affective disorders. Her studies frequently employ rodent models of amnesia, depression, anxiety, and neurodegeneration, evaluating compounds such as nicotine, memantine, flavonoids, and novel heterocyclic derivatives. The keywords across her work emphasize memory, behavior, receptors, animal models, brain, and drug effects, indicating a strong translational orientation toward CNS drug development.

Scientific Recognition:

• ORCID: 0000-0001-8270-9635
• Scopus, EuropePMC, Crossref profiles active
• Approximate Hirsch index (H-index) available via institutional repository
• Recipient of 4 documented achievements (specifics not detailed)

Academic Leadership and Funding: Professor Biała has promoted 11 doctoral theses, indicating significant mentorship in training future scientists. She has led 4 research projects, suggesting sustained grant support and project leadership. Her extensive publication record (397 publications) and patent ownership reflect high productivity and innovation in her field.

Laboratory and Research Group: She leads research within the Chair and Department of Pharmacology and Pharmacodynamics, utilizing animal models to study CNS drug actions. Her team likely focuses on behavioral pharmacology, molecular neuropharmacology, and drug screening using transgenic and pharmacologically induced models of neurological and psychiatric conditions.